Article Listing - Needham: Teva remains top dog in generics pricing
ARTHRITIS "NEGLECTED" IN THE UK
16 March 1992
Although arthritis is estimated to affect about 20 million people in the UK, it is considered a neglected disease. Furthermore,...
REPLIGEN'S rPF4
16 March 1992
Massachusetts-based Repligen Corp has established a partnership to support the $45 million cost of the development of its recombinant platelet...
NEW PRODUCT PHASE FOR BRITISH BIO-TECH
16 March 1992
British-biotechnology Group will look back on 1991 as a milestone year in the company's history, according to chairman Brian Richards,...
UPJOHN "DOWNGRADE"
16 March 1992
Because of concerns regarding side effects and their impact on the sales of Upjohn's sedative Halcion (triazolam), now around $260...
ITALY'S MENARINI TO INVEST ABROAD
16 March 1992
Italian pharmaceutical concern Menarini has given up on its scheme to set up a plant on the island of Elba,...
STOCK MARKET COMMENTARY: TOKYO
16 March 1992
TOKYO: stocks declined in a narrow trading range last week. Although volume remained low, the market did not have enough...
STOCK MARKET COMMENTARY: EUROPE
16 March 1992
EUROPE: was mixed last week, with strong performance in Sweden and a poor one in Italy, where Pierrel was...
ROUSSEL-UCLAFS MIFEGYNE
16 March 1992
- Roussel-Uclaf's progesterone antagonist abortifacient product Mifegyne (mifepristone) is to be tested as a first-line therapy for breast cancer in...
KANEBO MONOCLONAL ANTIBODIES
16 March 1992
- Japanese diversified textile and cosmetics company Kanebo Ltd plans to introduce technology for a humanized monoclonal antibody, the Smart...
GOOD GROWTH FOR RHONE-POULENC
9 March 1992
At Rhone-Poulenc, "the aggressive marketing effort on promotion-responsive products, supplemented by a roll-out of at least eight new medium-sized drugs,...
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
